Objective: Patients with triple-negative breast cancer (TNBC) frequently develop resistance to chemotherapy. Studies have shown that microRNAs (miRNAs) are often aberrantly expressed in TNBC and are associated with drug resistance. However, a prognostic strategy that correlates miRNAs with chemotherapy resistance remains largely unknown. Methods: To identify breast cancer chemoresistance-associated miRNAs, the miRNA microarray dataset GSE71142 was downloaded from the Gene Expression Omnibus database. Differentially expressed miRNAs (DE-miRNAs) in chemoresistant groups were identified using the LIMMA package in R. Potential target genes were predicted using the miRTarBase 9. Functional and pathway enrichment analyses was done using WebGestalt. A protein-protein interaction network was visualized using Cytoscape software. The top six hub genes regulated by DE-miRNAs were identified using the random forest model. The chemotherapy resistance index (CRI) in TNBC was defined as sum of the median expression levels of the top six hub genes. The association of CRI with distant relapse risk was evaluated using point-biserial correlation coefficient in the validation cohorts of patients with TNBC. The correlation between CRI and cumulative hazard rate was estimated using the Cox model, and the predicted rate of distant relapse was obtained from the Breslow-type estimator of the survival function. All statistical computations were performed using Origin2019b. Results: A total of 12 DE-miRNAs were screened, including six upregulated and six downregulated miRNAs in chemoresistant breast cancer tissues compared with chemosensitive tissues. Based on fold changes, miR-214-3p, miR-4758-3p, miR-200c-3p, miR-4254, miR-140-3p, and miR-24-3p were the top six most upregulated miRNAs, whereas miR-142-5p, miR-146-5p, miR-1268b, miR-1275, miR-4447, and miR-4472 were the top six most downregulated miRNAs. The top three hub genes for upregulated miRNAs were RAC1, MYC, and CCND1 and for downregulated miRNAs were IL-6, SOCS1, and PDGFRA. CRI was significantly associated with the risk of distant relapse. Conclusion: CRI predicted survival benefits with reduced hazard rate.
Sameer C, A., Shah, M., Nandy, D., & Gupta, R. (2023). Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer. Asian Pacific Journal of Cancer Prevention, 24(6), 2043-2053. doi: 10.31557/APJCP.2023.24.6.2043
MLA
Ahammad Sameer C; Manan Shah; Dipayan Nandy; Reeshu Gupta. "Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer". Asian Pacific Journal of Cancer Prevention, 24, 6, 2023, 2043-2053. doi: 10.31557/APJCP.2023.24.6.2043
HARVARD
Sameer C, A., Shah, M., Nandy, D., Gupta, R. (2023). 'Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer', Asian Pacific Journal of Cancer Prevention, 24(6), pp. 2043-2053. doi: 10.31557/APJCP.2023.24.6.2043
VANCOUVER
Sameer C, A., Shah, M., Nandy, D., Gupta, R. Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2023; 24(6): 2043-2053. doi: 10.31557/APJCP.2023.24.6.2043
)